Abstract Details

Title Efficacy of OnabotulinumtoxinA Treatment in Episodic Migraine

Topic Headache

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 12-003

Objective

The aim of our study was to evaluate the efficacy, tolerability, and impact on disease burden of BoNT-A use in preventing
episodic migraine (EM).

Background

OnabotulinumtoxinA (BoNT-A) is approved for prophylactic treatment of chronic migraine (CM) only.

Design/Methods

This is a prospective study included migraine patients, aged 18 -65 years, and completed one year treatment with BoNT-A. Patients received 4 courses of BoNT-A treatment. Patient’s headache was assessed by headache diary at baseline, and before every injection. Migraine Specific Quality of Life Questionnaire (MSQ) and work productivity were collected at baseline and in their last visit. Adverse events (AEs) were reported.

Results The study recruited 210 patients. Between baseline and the final visit, there were a significant reduction in migraine days, analgesic consumption days, and headache severity (9.54 +1.70 versus 4.58+ 2.77, P < 0.001), (8.47 +1.49 versus 2.98+ 0.21, P < 0.001), (8.37+ 0.72versus 2.54 +0.18, P < 0.001), respectively. BoNT-A treatment reduced the mean number of missed hours from work and daily activities over a 7-day period (4.63 +2.39 versus 6.26 +2.04, P < 0.001); (2.24+ 3.30 versus 3.94 +3. 45; P < 0.001). Treatment with BoNT-A significantly improved the MSQ scores at last visit versus baseline visit, MSQ Role Function- Restrictive (51.55 +29.12 vs.26.89+ 17.42; P<0.001), MSQ Role Function-Preventive (56.07+ 24.73 vs. 30.64+ 15.25; P<0.001), and for MSQ Emotional Function (76.47 +115.29 vs. 35.12+ 20.83; P<0.001). 54 patients (14.4%) experienced mild, short-lasting AEs.

Conclusions

BoNT-A is an effective and well tolerated therapy in the prophylaxis of EM, improving MSQ and WPAI.

Authors/Disclosures
Malak AlMojel, MD (Amiri Hospital) PRESENTER	Dr. AlMojel has nothing to disclose.
Jasem Y. Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department)	Dr. Al-Hashel has nothing to disclose.
Raed Alroughani, MD, FAAN	Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
Samar F. Ahmed, MD	Dr. Ahmed has nothing to disclose.

��ɫ��

��ɫ��